The Gene Therapy Superhighway
Gene Therapy companies need delivery devices for their therapies and device companies must increasingly embrace biotechnologies to improve and differentiate their increasingly commoditized offerings. In a handful of device/biotech deals signed in the pas year, device companies are gaining exclusive worldwide rights to new cardiovascular gene therapies. The next meeting ground for gene therapies and devices: orthobiologics.
You may also be interested in...
Why Millions from California Won't Get VCs to Fund Stem Cell Start-Ups--But What Will
Despite the millions of dollars from public initiatives, particularly in California, to fund stem-cell research, VCs will still probably stay away until Big Pharma and Big Biotech show more of their own R&D interest in the area.
One-Page Patient Medication Information Document Moves Forward Under Proposed Rule
After decades of work, the US FDA released proposed requirements for a simplified version of the Medication Guide for all products. Electronic distribution in lieu of paper ‘upon a patient’s request’ would be allowed. Comments sought on the value of consumer testing of the documents.
Japan Eyes Cutting Reimbursement For COVID-19 Drugs
Japan will end full reimbursement coverage for COVID-19 therapeutic drugs from October, after downgrading the status of the virus to the same level as seasonal flu in early May. As authorities discuss the possible coverage reduction, a larger than usual price cut may also be applied to Shionogi's oral COVID antiviral Xocova.